Skip to main content
SpringerLink
Log in

The Treatment of Sepsis with Interleukin-1 Receptor Antagonist

  • Chapter
Sepsis

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICM,volume 18))

  • 133 Accesses

Abstract

Compelling experimental evidence and considerable clinical experience indicate that the proinflammatory cytokines are central to the pathogenesis of septic shock [1, 2]. Interleukin-1 (IL-1) and tumor necrosis factor-α (TNF) play an essential protective role in the priming and initiation of the host innate and acquired immune response to localized infection and inflammatory stimuli. However, excess systemic activation of these monocyte/macrophage-derived cytokines is clearly detrimental to the host and participate in the diffuse endothelial injury and disordered hemodynamic sequelae of sepsis [3]. In addition to their own intrinsic inflammatory actions, IL-1 and TNF stimulate the synthesis of additional host-derived inflammatory mediators such as platelet activating factor, eicosanoid compounds, interleukin-8 (IL-8), and other mediators which act in concert to produce septic shock. It has now become evident that activation of the cytokine-dependent nitric oxide synthase system by IL-1 and TNF is primarily responsible for the hypotension observed in septic shock [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bone RC (1991) Pathogenesis of Sepsis. Ann Intern Med 115:457–465

    PubMed  CAS  Google Scholar 

  2. Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471–1477

    Article  PubMed  CAS  Google Scholar 

  3. Dinarello CA (1991) The proinflammatory cytokines: Il-1 and TNF in the treatment of septic shock syndrome. J Infect Dis 136:1177–1184

    Article  Google Scholar 

  4. Kilbourn RG, Gross SS, Jubran A et al (1990) NG-methyl-L-arginine inhibits TNF-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87:3622–3632

    Article  Google Scholar 

  5. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) IL-1 induces a shock-like state in rabbits. Synergism with TNF and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162–1172

    CAS  Google Scholar 

  6. Dinarello CA (1988) Biology of IL-1. FASEB J 2:108–115

    PubMed  CAS  Google Scholar 

  7. Secklinger P, Dayer JM (1987) IL-1 inhibitors. Ann Inst Pasteur/Immunol 138:461–516

    Article  Google Scholar 

  8. Arend WP, Joslin FG, Thompson RC, Hannum CH (1989) An IL-1 inhibitor from human monocytes. Production and characterization by logic properties. J Immunol 143:1851–1858

    CAS  Google Scholar 

  9. Dinarello CA, Thompson RC (1991) Blocking IL-1: IL-1ra in vivo and in vitro. Immunol Today 12:404–410

    Article  PubMed  CAS  Google Scholar 

  10. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) IL-1ra binds to the 80 kDa IL-1 receptor but does not initiate IL-1 signal transduction. Biol Chem 266:10331–10336

    CAS  Google Scholar 

  11. Eisenberg SP, Evans RJ, Arend WP et al (1990) Primary structure and functional expression from complimentary DNA of a human IL-lra. Nature 343:141–146

    Article  Google Scholar 

  12. Ju G, Labriola-Tompkins E, Campen CA et al (1991) Conversion of the IL-1ra into an agonist by site-specific mutagenesis. Proc Natl Acad Sci USA 88:2658–2662

    Article  PubMed  CAS  Google Scholar 

  13. McIntyre KW, Stepan GJ, Kolinsky JD et al (1991) Inhibition of IL-1 binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1ra and anti-IL-1 receptor monoclonal antibody. J Exp Med 173:931–939

    Article  PubMed  CAS  Google Scholar 

  14. Ulich TR, Yin S, DelCastillo J, Eisenberg SP, Thompson RC (1991) The intratracheal administration of endotoxin and cytokines. III. The IL-1ra inhibits endotoxin and IL-1 induced acute inflammation. Am J Pathol 138:521–524

    CAS  Google Scholar 

  15. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to IL-1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029–1032

    Article  PubMed  CAS  Google Scholar 

  16. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) IL-1ra reduces mortality from endotoxin shock. Nature 348:550–552

    Article  PubMed  CAS  Google Scholar 

  17. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for IL-1 prevents E. coli induced shock in rabbits. FASEB J 5:338–343

    CAS  Google Scholar 

  18. Fischer E, Marano MA, VanZee JK et al (1992) IL-1 receptor blockade improves survival in hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sub-lethal endotoxemia. Clin Invest 89:1551–1557

    Article  CAS  Google Scholar 

  19. Aiura K, Gelfand JA, Wakabayashi G et al (1991) IL-1ra blocks hypotension in a rabbit model of gram-positive septic shock. Cytokine 3:498

    Google Scholar 

  20. Granowitz EV, Porat R, Mier JW et al (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant IL-1ra in healthy humans. Cytokine 4:353–360

    Article  PubMed  CAS  Google Scholar 

  21. Granowitz EV, Santos AA, Poutsiaka DD et al (1991) Production of IL-1ra during experimental endotoxaemia. Lancet 33A: 1423–1424

    Article  Google Scholar 

  22. Walsh CE, Liu JM, Anderson SM, Russio JL, Nienhuis AS, Young MS (1992) A trial of recombinant IL-1 in patients with severe refractory aplastic anemia. Br J Haematol 80:106–110

    Article  PubMed  CAS  Google Scholar 

  23. Bone RC, Fisher CJ, Clemmer TP et al (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393

    Article  PubMed  CAS  Google Scholar 

  24. Fisher CJ, Slotman G, Opal S, Pribble J, Catalano M, IL-1ra Sepsis Study Group (1991) Results of a phase II study of IL-1ra in the treatment of sepsis syndrome. American College of Chest Physicians, 57th annual meeting, San Francisco, California

    Google Scholar 

  25. Opal SM, Fisher CJ, Slotman GJ et al and the IL-1ra Sepsis Study Group (1992) Phase II IL-1ra sepsis syndrome trial: analysis of clinical, cytokine, and microbial features with outcome. 32nd annual meeting of the interscience conference of antimicrobial agents and chemotherapy, Anaheim, California (abstract 1570)

    Google Scholar 

  26. Gordon G, Fisher CJ, Opal SM, Pribble J, Catalano M (1992) Cost-effectiveness of IL-1ra in sepsis. Clin Res 40:254A (abstract)

    Google Scholar 

  27. Fisher CJ, Dhainaut J-F, Pribble JP, Knause WA, IL-1ra Study Group (1993) A study evaluating the safety and efficacy of human recombinant IL-1ra in the treatment of patients with sepsis syndrome. Presented at the 13th international symposium on intensive care and emergency medicine, Brussels, Belgium

    Google Scholar 

  28. Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829–1835

    Article  PubMed  CAS  Google Scholar 

  29. Knaus WA, Harrell FE, Fisher CJ et al (1993) The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 270:1233–1241

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. M. Opal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. J. Fisher Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Pribble
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Anästhesiologie und Intensivtherapie, Klinikum der Friedrich Schiller-Universität Jena, Bachstraße 18, 07740, Jena, Germany

    Konrad Reinhart

  2. Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Steglitz der FU Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Klaus Eyrich

  3. Department of Anesthesiology and Critical Care Medicine, Hadassah Hebrew University, Medical Center, P. O. Box 12000, 91120, Jerusalem, Israel

    Charles Sprung (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Opal, S.M., Fisher, C.J., Pribble, J. (1994). The Treatment of Sepsis with Interleukin-1 Receptor Antagonist. In: Reinhart, K., Eyrich, K., Sprung, C. (eds) Sepsis. Update in Intensive Care and Emergency Medicine, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85036-3_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85036-3_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85038-7

  • Online ISBN: 978-3-642-85036-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation